Chardan Capital Markets
http://www.chardancm.comChardan Capital Markets is an international investment bank headquartered in New York City, with offices in Los Angeles and Beijing. Chardan provides a wide array of financial services including investment banking, capital markets, international trading and equity research. The investment banking group focuses on providing banking and advisory services to private and public companies in small and mid-cap markets. The institutional coverage of Chardan Capital Markets spans North America, Europe and Asia. Chardan Capital Markets LLC is a registered broker-dealer with the U.S. Securities and Exchange Commission and is a member of the following: Financial Industry Regulatory Authority (FINRA); Municipal Securities Rulemaking Board (MSRB); Securities Insurance Protection Corporation (SIPC); NASDAQ Stock Market and the NYSE Arca, Inc.
View Older Stories View More Recent Stories
-
Taysha Gene Therapies (TSHA) PT Raised to $67.50 at Chardan Capital Markets
-
Provention Bio Inc. (PRVB) PT Lowered to $22.50 at Chardan Capital Markets
-
Homology Medicines Inc. (FIXX) Promotes Tim Kelly to COO Position
-
Homology Medicines Announces Promotion of Tim Kelly to Chief Operating Officer
-
Form S-1/A Chardan NexTech Acquisit
-
MBP Announces Webinar on SPAC Investing 101: A Guide to Wall Street's Hottest Asset Class
-
Better Therapeutics to Become Publicly Traded via Merger with Mountain Crest Acquisition Corp. II (MCAD)
-
Better Therapeutics to Become Publicly Traded Prescription Digital Therapeutics Company via Merger with Mountain Crest Acquisition Corp. II
-
Achilles Therapeutics Announces Closing of $175.5 million Initial Public Offering
-
Dawson James Hires Veteran Analyst - James McIlree
-
Dawson James Hires Veteran Analyst - James McIlree
-
Nocturne Acquisition Corporation Announces Closing of $100 Million Initial Public Offering
-
Taysha Gene Therapies to Participate in Upcoming April Investor Healthcare Conferences
-
uniQure to Participate in Multiple Upcoming Industry Conferences in April
-
Form SC 13G Chardan Healthcare Acqui Filed by: Altium Capital Management LP
-
AgeX Therapeutics Reports Fourth Quarter and Annual 2020 Financial Results and Provides Business Update
-
Penny Stocks To Buy Now According To 3 Top Wall Street Analysts
-
IPO for Achilles Therapeutics plc (ACHL) Opens Flat, Drifts Lower
-
IPO for SPAC Nocturne Acquisition Corporation (MBTC) Opens at $10.01
-
Nocturne Acquisition Corporation Announces Pricing of $100 Million Initial Public Offering
-
Achilles Therapeutics plc (ACHL) Prices 9.75M Share IPO at $18/Sh
-
Sensorion Senior Management to Attend Four Conferences in April 2021
-
Achilles Therapeutics Announces Pricing of Initial Public Offering
-
Achilles Therapeutics Announces Pricing of Initial Public Offering
-
CohBar Reports Fourth Quarter 2020 Financial Results and Provides Business Update
-
CohBar Reports Fourth Quarter 2020 Financial Results and Provides Business Update
-
Passage Bio to Participate in Upcoming April Investor Conferences
-
Passage Bio to Participate in Upcoming April Investor Conferences
-
Form S-1/A CHARDAN NEXTECH ACQUISIT
-
Modiv Acquisition Corp. (“MAC SPAC”) Announces Filing of Registration Statement
-
Solid Biosciences Announces Closing of Public Offering and Full Exercise of Over-Allotment Option
-
Renovacor to Come Public Through Merger with SPAC Chardan Healthcare Acquisition 2 Corp. (CHAQ)
-
Form 8-K Chardan Healthcare Acqui For: Mar 22
-
Form DEFA14A Chardan Healthcare Acqui
-
Renovacor, Inc. to Merge with Chardan Healthcare Acquisition 2 Corp.
-
Chardan Expands Research Team, Welcomes Managing Director and Director of Research
-
Form S-1/A CHARDAN NEXTECH ACQUISIT
-
Solid Biosciences (SLDB) Prices 21.74M Share Common Offering at $5.75/Sh
-
Solid Biosciences Announces Pricing of Public Offering of Common Stock
-
Adverum Announces Board Slate for 2021 Annual Meeting and Reiterates Commitment to Stockholder Value Creation
-
Solid Biosciences (SLDB) to Offer $85M in Common Stock
-
Solid Biosciences Announces Proposed Public Offering of Common Stock
-
Forte Biosciences Inc. (FBRX) PT Lowered to $105 at Chardan Capital Markets
-
4D Pharma Announces Private Placement
-
Solid Biosciences (SLDB) PT Raised to $20 at Chardan Capital Markets
-
ContraFect Corp. (CFRX) PT Raised to $17.50 at Chardan Capital Markets
-
Homology Medicines Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Highlights
-
Outcome Capital Expands Life Science Practice with Addition of Digital Health Industry Veterans
-
Form S-1/A CHARDAN NEXTECH ACQUISIT
-
Form S-1/A Chardan NexTech Acquisit

